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This mini-review summarizes our present view of the biochemical alterations associated with mitochondrial DNA (mtDNA) point
mutations. Mitochondrial cytopathies caused by mutations of mtDNA are well-known genetic and clinical entities, but the biochemical
pathogenic mechanisms are often obscure.
Leber’s hereditary optic neuropathy (LHON) is due to three main mutations in genes for complex I subunits. Even if the catalytic activity
of complex I is maintained except in cells carrying the 3460/ND1 mutation, in all cases there is a change in sensitivity to complex I inhibitors
and an impairment of mitochondrial respiration, eliciting the possibility of generation of reactive oxygen species (ROS) by the complex.
Neurogenic muscle weakness, Ataxia and Retinitis Pigmentosa (NARP), is due to a mutation in the ATPase-6 gene. In NARP patients ATP
synthesis is strongly depressed to an extent proportional to the mutation load; nevertheless, ATP hydrolysis and ATP-driven proton translocation
are not affected. It is suggested that the NARP mutation affects the ability of the enzyme to couple proton transport to ATP synthesis.
A point mutation in subunit III of cytochrome c oxidase is accompanied by a syndrome resemblingMELAS: however, nomajor biochemical
defect is found, if we except an enhanced production of ROS. The mechanism of such enhancement is at present unknown.
In this review, we draw attention to a few examples in which the overproduction of ROS might represent a common step in the induction of
clinical phenotypes and/or in the progression of several human pathologies associated with mtDNA point mutations.
D 2004 Elsevier B.V. All rights reserved.Keywords: Mitochondrial cytopathy; LHON; NARP; Complex I; ATP synthase; Cytochrome oxidase subunit III1. Introduction
Mitochondrial diseases (mitochondrial cytopathies) are a
heterogeneous group of disorders characterized by dysfunc-
tion of mitochondrial oxidative phosphorylation (OXPHOS)
and caused by mutations of either nuclear DNA or mitochon-
drial DNA (mtDNA) [1]. Point mutations in mitochondrial
genes encoding for either ribosomal RNA, transfer RNA, or
polypeptides are maternally inherited, while large-scale rear-
rangements of mtDNA (deletions and/or duplications) are
usually sporadic. Mutations in the mitochondrial genome
have been described in a heterogeneous group of disorders in
which the nervous system and the skeletal muscle are
predominantly affected.0005-2728/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbabio.2004.03.013
* Corresponding author. Tel.: +39-51-2091229; fax: +39-51-2091217.
E-mail address: lenaz@biocfarm.unibo.it (G. Lenaz).Diseases due to mtDNA mutations are well-defined clin-
ical syndromes and their genetics is known; however, the
pathogenesis and the relation between molecular target of the
mutation and clinical phenotype are often obscure [2]. The
main biochemical consequence of deletions and pathogenic
mtDNA mutations affecting tRNAs is impairment in respi-
ratory capacity of the cell and ATP synthesis, possibly due to
defects in the mitochondrial translation mechanism [1]. A
bioenergetic defect is generally apparent only above a thresh-
old of mutation load, indicating that the normally synthesized
complexes may take over OXPHOS to a sufficient extent for
the cellular needs.
In the case of point mutations affecting structural
genes, a simple direct biochemical consequence of the
protein alteration due to the mutation cannot be usually
found. The association of different syndromes with the
same mutation, and of different mutations with the same
syndrome, has prompted speculation that additional mech-
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environmental factors, or even the aging process itself,
may be important contributory determinants of phenotypic
expression [2]. In addition, there is insufficient knowledge
on some basic aspects of mitochondrial structure and
function in different tissues, such as the rate-limiting steps
and the organization of the OXPHOS system as individual
complexes or supercomplexes [3], the role of the respira-
tory chain in production of reactive oxygen species (ROS)
[4], and the role of mitochondrial lesions within the cell
environment, in particular the cross-talk between altered
mitochondria and nucleus [5]. All of these aspects may be
critical in the pathogenesis of the mitochondrial cytopa-
thies and their expression in selected tissues.
Diagnosis of mitochondrial diseases is based on bio-
chemical, morphological and molecular genetic analyses
of blood, muscle or skin biopsies. Because it is often
difficult to obtain enough material to study pathogenetic
mechanisms, patient-derived cell culture models have been
used to establish bioenergetic deficits and to analyze the
biochemical phenotypes. A cell culture model most ex-
tensively used for the study of mitochondrial disorders is
the cybrids (cytoplasmic hybrids) system, first described
by King and Attardi [6]. Cybrids are generated by fusing
enucleated cytoplasts from patients’ cells harboring
mtDNA mutations with mtDNA-less (Uj) cells, grown
under selection, and subcloned. This technique permits the
analysis of cybrids that are isogenic for mtDNA and have
a neutral nuclear background. Cybrids may contain not
only homoplasmic wild-type and homoplasmic mutant
mtDNA, but also different percentages of mutant mole-
cules from the same patient. Several mtDNA mutations
have been studied and characterized using this system.Table 1
Complex I redox activity, complex I-dependent respiration and inhibitor
sensitivity in LHON patients (see Refs. [12,13,15–17])
3460/ND1 11778/ND4 14484/ND6
















Rotenone decreased decreased decreased
Rolliniastatin-2 normal normal normal
Amytal normal normal normal
Myxothiazol – increased increased
NBQH2 – increased increased2. Biochemical impairments in Leber’s hereditary optic
neuropathy (LHON)
Since mtDNA mutations show a wide spectrum of
clinical, biochemical, and tissue-specific phenotypes, it is
helpful to examine multiple aspects of bioenergetics in
culture models to understand their underlying pathophysiol-
ogy. This involves analysis of check points in energy
metabolism, such as (a) the end point of glycolysis at the
level of lactate and pyruvate, (b) the terminal step of
oxidative phosphorylation, resulting in ATP synthesis, and
(c) overall respiratory chain function, as reflected by rates of
oxygen consumption. In this study we have analyzed some
key biochemical parameters that reflect the global bioener-
getic status of LHON cybrid cell lines. This is a maternally
inherited form of degeneration of the retinal ganglion cells,
leading to loss of central vision [7]. Three frequent, and a
few other rare mutations affecting ND subunits of complex I
[7,8] are established as pathogenic. The three most frequent
mutations are those found at positions G11778A/ND4,
G3460A/ND1, and T14484C/ND6.Biochemical investigations of the three most frequent
mutations revealed some biochemical changes in measur-
able aspects of complex I function that are usually subtle
and of modest entity [9]. Only the 3460/ND1 mutation
showed a consistent reduction in complex I electron transfer
activity (60–80%) [10–12], while both 11778/ND4 and
14484/ND6 mutations had normal or slightly reduced ac-
tivities [12–14]. Moreover, no differences were usually
detected between cells derived from LHON patients and
cells from unaffected carriers of LHON mutations [12,13].
Further studies on the sensitivity of the complex to
different specific inhibitors reported a reduced sensitivity to
rotenone and an enhanced sensitivity to quinol product
inhibition, while sensitivity to other complex I inhibitors
not interfering with the CoQ binding site, such as rollinias-
tatin-2 or amytal, was unchanged (Table 1). These results
consistently suggest that all three LHON mutations interfere
with the interaction of complex I with the ubiquinone
substrate (CoQ) [12,13,15,16], indicating that the ubiquinone
binding site may be affected by the LHON mutations and/or
that ubisemiquinone intermediates may have a reduced
stability [17].
Three major consequences may derive from the complex
I dysfunction reported in LHON: first, respiratory function
may be disturbed at the level of quinol product release
because of the impaired electron flow, leading to decreased
total respiratory activity; in addition, due to alteration of the
hydrophobic quinone binding site(s), proton pumping
through complex I may be defective thereby affecting
energy conservation; finally, an increase of ROS generation
may occur as a consequence of altered electron flow, as
reported in the case of nuclear complex I mutations [18], or
because unstable ubisemiquinone radicals may rapidly
dismutate after reacting with oxygen [17]. Studies are in
due course in our laboratory using osteosarcoma-derived
cybrids carrying each of the LHON mutations to evaluate
NAD- and succinate-dependent respiration and ATP
synthesis. Preliminary data seem to indicate that complex
I-dependent ATP synthesis is affected by all three muta-
tions, as reflected by the slight reduction of total ATP
Table 2
Respiratory activities in digitonin-permeabilized cybrids carrying the
11778/ND4 mutation
Wild-type cybrids 11778/ND4 cybrids
Glutamate/Malate Succinate Glutamate/Malate Succinate
(nmol O2/min/mg) (nmol O2/min/mg)
State 4 0.030F 0.006 0.057F 0.015 0.046F 0.003 0.080F 0.004
State 3 0.111F 0.029 0.172F 0.029 0.107F 0.040 0.180F 0.043
RCR 3.7F 0.5 3.1F 0.5 2.1F 0.9* 2.3F 0.6
P < 0.05.
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thesis does not appear significantly affected.
Analysis of State 4 and State 3 respiration in cybrids
carrying the 11778/ND4 mutation reveals that the decrease
of respiratory control ratio is due to real uncoupling, with
increase of State 4 activity; such uncoupling occurs both
with glutamate plus malate and with succinate as substrates,
and therefore appears to be a secondary effect (Table 2).
The present results are not in contrast with the currently
favored hypothesis that besides an energy defect, overpro-
duction of ROS may represent a major element in LHON
pathophysiology [19]. Actually, the uncoupling effect found
in the 11778/ND4 mutation with succinate may suggest that
the effect is the result of ROS overproduction. Inhibition of
complex I with rotenone and other CoQ antagonists induces
an enhancement of superoxide radical production by the
complex [20]; the site of ROS production is identified in a
region upstream of bound ubiquinone, such as FMN [21], or
iron sulfur clusters N2 [20] or N1a [22], thus, an enhanced
ROS production is likely to occur under conditions when
complex I activity is impaired, as in cells carrying the
G3460A/ND1 mutation. This hypothesis is supported by
the increased ROS generation after partial complex I inhibi-
tion [23]. However, the hypothesis is more difficult to
reconcile with the 11778 mutation where electron flow is
normal. Although ubiquinone does not normally represent a
source of ROS in complex I, it was suggested that the
destabilization of bound ubiquinone [17] in the complex
may enhance the production of ROS by the complex; the
apoptotic cell death occurring in LHON cybrids carrying the
11778 mutation, as well as others, incubated in galactose
medium [24] may be the result of increased ROS generation.
On the long term, bioenergetically compensated cells may
suffer from chronic ROS overproduction and the compro-
mised oxidative phosphorylation in LHON may play a major
role once the threshold for cell death is crossed [24].Fig. 1. Correlation of the rate of ATP synthesis with the extent of
heteroplasmy in platelets from NARP subjects (cf. Ref. [29]).3. Impairment of ATP synthase in NARP syndrome
The Neurogenic muscle weakness, Ataxia and Retinitis
Pigmentosa (NARP) syndrome, and the maternally inherited
Leigh syndrome (MILS), among others, are both caused by
mutations at the 8993 bp in mtDNA [25,26]. The T!G
mutation changes Leu-156 with Arg in the ATPase-6subunit gene (subunit a) of the mitochondrial ATP synthase
complex. The variable degree of heteroplasmy is associated
with different clinical expressions [25–27].
Coupled submitochondrial particles prepared from plate-
lets of NARP patients showed a dramatic decrease of
succinate-driven ATP synthesis rate, but both ATP hydroly-
sis rate and ATP-driven proton translocation were minimally
affected [28]. This implies a different effect of the mutation
on the F0F1 function and/or an unidirectional impairment of
proton flow, only when the enzyme works physiologically
(i.e. cytosol to matrix proton flow). There was a close
relationship between tissue heteroplasmy, expression of the
biochemical defect of ATP synthesis in platelets, and clinical
involvement [29]. Furthermore, little variation in hetero-
plasmy among different tissues in each patient was reported.
Fig. 1 shows that the biochemical defect is strictly correlated
with the degree of heteroplasmy without any evidence of a
biochemical threshold. However, 60% to 75% mutant
mtDNA is required for clinical expression of typical central
nervous systems symptoms [30,31].
In order to unravel the biochemical mechanism underlying
decreased ATP synthesis, we are measuring the proton
transport from cytosol to matrix during ATP synthesis in
digitonin-permeabilized lymphocytes of NARP patients. The
method involves exploitation of the kinetics of Rhodamine-
123 fluorescence quenching in presence of succinate and
ADP, when protons are both pumped out of the matrix by the
respiratory chain complexes and allowed to diffuse back in
the matrix through ATP synthase during ATP synthesis; the
overall quenching rate is proportional to the steady-state
membrane potential under State 3 conditions. The initial rate
of quenching is significantly enhanced by oligomycin, which
abolishes the ADP-driven potential decrease due to backflow
of protons during ATP synthesis [32].
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patient show that the mitochondrial membrane potential,
studied as above, is slightly enhanced with respect to
controls, suggesting that mutation seems to hardly affect
the F0 permeability to protons. The results are also in line
with the previously found normal ATP-driven proton trans-
location [28]. Furthermore, the reduced backflow of protons
might induce substantial overproduction of ROS [33] as an
additional defect superimposed to the defect of extremely
reduced ATP synthesis, especially when nearly homoplas-
mic levels of mutant mtDNA are reached: this may account
for the shift from the rather mild NARP to the devastating
Leigh disease [29].Fig. 2. ROS generation by cybrids carrying the 9957 COX III mutation in
comparison with the parent osteosarcoma cell line. ROS were evaluated
using the fluorescent probe DCFA [44].4. Enhanced ROS generation in cybrids harboring a
COX III mtDNA mutation (T9957C) associated with
MELAS
A missense mutation in the gene encoding COX III at
position 9957 of mtDNAwhich causes a F251L amino acid
substitution, a highly conserved residue among different
species, has been reported in a patient affected by mitochon-
drial encephalomyopathy clinically resembling MELAS
(mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes) [34]. The COX III residue Phe-251 in
humans is located in the hydrophobic core of the last
transmembrane helix of the subunit [35], and is homologous
to Phe-263 in Paracoccus denitrficans [34]. When this
residue was converted to Leu, there was a reduced growth
of the mutant strain, reduction of proton pumping stoichi-
ometry of COX, and reduction of membrane potential [36].
Therefore, an intrinsic uncoupling of COX (reduced effi-
ciency of DlH + generation) may be the cause of the
mitochondrial dysfunction in the patient harboring the
9957 mtDNA mutation. A role of Subunit III in proton
translocation through the D proton pathway has been sug-
gested [37,38]. Alternatively, a defect of COX III might
result in altered subunit assembly [39]: there is increasing
evidence for a role of subunit III in COX assembly [40–43].
Cybrids produced from the patient’s fibroblasts and an
osteosarcoma-derived cell line have been kindly provided
by Dr. G. Manfredi and investigated in order to enlighten the
biochemical defect responsible for the disease.
We found no major decrease of either cytochrome
oxidase activity or total respiration nor any change of
mitochondrial membrane potential in the cybrids in com-
parison with the parent osteosarcoma cell line; on the other
hand, we did find a significant increase of ROS production
by incubation of the cells with dichlorofluorescin diacetate
and analyzing the fluorescence of the oxidized product
dichlorofluorescein (Fig. 2).
The mechanism of enhanced ROS production in the
mutant cells is not clear: in general, ROS are produced by
complexes I and III when the electron flow is lowered and
the electron carriers are mostly in the reduced state [33].Since no change in oxidation rate of the chain is apparent,
this mechanism has little support. On the other hand, no case
has been described so far of ROS generation directly at the
level of cytochrome oxidase, where the electron transfer to
oxygen does not lead to release of partially reduced oxygen
intermediates.5. Conclusions
The elusive nature of the biochemical defects responsible
for the clinical phenotype of mtDNA genetic disorders is
largely due to technical difficulties in the biochemical
characterization of the dysfunctions. The availability of
transmitochondrial cell lines (cybrids) greatly facilitates
the efforts to unveil the biochemical mechanisms of mito-
chondrial diseases. Even when no clear alterations are
apparent in the simple enzymology of the affected com-
plexes, in-depth analysis may reveal molecular defects
responsible for decreased ATP synthesis or enhanced pro-
duction of ROS. Both such defects may coexist in the same
cells, but to different extents in different tissues, thus
complicating the understanding of the pathogenic mecha-
nisms of the diseases. Nevertheless, the results discussed in
the present mini-review based on data from our and other
laboratories are relevant in order to better understand the
biochemical mechanisms altered by the mtDNA point
mutations described, and might be important to design
appropriate therapeutic strategies to at least slow the pro-
gression of the mitochondrial diseases.Acknowledgements
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